MedTrace Logo

Open Label Safety Study of a Birch Pollen Allergen Extract

NCT00818181 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2013-03-11

No results posted yet for this study

Summary

This trial is performed to assess safety of a sublingual birch pollen extract.

Conditions

  • Rhinoconjunctivitis

Interventions

DRUG

Biological: AL0206st

Sponsors & Collaborators

  • Allergopharma GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Nicolas Hunzelmann, Prof. Dr. · University of Cologne

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-02-28
Completion
2010-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00818181 on ClinicalTrials.gov